Compositions and methods for treating cancer using rhoa dominant negative forms
A RHOA, cancer technology, applied in biochemical equipment and methods, peptide preparation methods, chemical instruments and methods, etc., can solve problems such as lack of molecular targeted therapy
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
example
[0296] The invention is further illustrated by the following examples, which should not be construed as limiting.
example 1
[0297] Example 1: Materials and methods of Example 2
[0298] a . mouse colony
[0299] Mist1-CreERT2, Cdh1flox / flox, Tomation / GFP mice carrying conditional alleles in which the loxP site is located next to exons 2-3 of Cdh1 were generously provided by Timothy C. Wang, Columbia University. Cre recombinase was activated by oral administration of tamoxifen (Sigma, T5648) TAM (1-5 mg / 0.2 ml corn oil, as indicated). The ethics committee of Dana-Farber Cancer Institute approved all animal studies and procedures.
[0300] b . Isolation and Culture of Mouse Gastric Organoids
[0301] A protocol previously described by Miyoshi et al. (2013) Nat. Prot. 8:2471-2482 was performed as follows: Mice were euthanized using chemicals, stomachs were opened longitudinally, and the contents of paper towels were roughly removed thing. Wash the tissue with ice-cold PBS in a 90 mm Petri dish, then shake vigorously with about 20 ml of ice-cold PBS in a 50 ml centrifuge tube. After washing,...
example 2
[0308] Example 2: RHOA dominant negative mutants kill CDH1-null cancer cells
[0309]Diffuse gastric cancer (DGC), a highly lethal variant of gastric cancer, is prone to early invasion and metastasis, and lacks effective molecularly targeted therapies. Initiation of DGC is often followed by loss of the tumor suppressor CDH1 encoding the cell adhesion protein E-cadherin. Reduction and / or loss of E-cadherin (CDH1) is a key hallmark of invasive lobular breast cancer, and loss-of-function mutations targeting CDH1 are present in 50%-60% of invasive lobular breast cancers and are thought to is an early event commonly observed in matched lobular carcinoma in situ (McCart Reed et al (2015) Breast Cancer Res. 17:12). Here we demonstrate that ectopic expression of small GTPase RHOA dominant-negative forms (e.g., T19N, G17V, G17E, etc.) lead to marked inhibition of proliferation and induction of cell death in CDH1-null cells (but not cells with intact CDH1). These results are diffused ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More - R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com



